As of Wednesday close, Harmony Biosciences Holdings Inc.’s (NASDAQ:HRMY) stock was down -$0.45, moving down -0.78 percent to $57.50. The average number of shares traded per day over the past five days has been 282,860 shares. 5 times new highs have been achieved over the past 5 days, with a $1.86 gain in that time frame. In the last twenty days, the average volume was 563,095, while in the previous 50 days, it was 520,608.
Since last month, HRMY stock rose 11.24%. Shares of the company fell to $49.83 on 10/24/22, the lowest level in the past month. A 52-week high of $61.55 was reached on 11/15/22 after having rallying from a 52-week low of $31.54. Since the beginning of this year, HRMY’s stock price has risen by 34.85% or $14.86, and marked a new high 22 times. However, the stock has declined by -6.58% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
HRMY stock investors should be aware that Harmony Biosciences Holdings Inc. (HRMY) stock had its last reported insider trading activity 2 days ago on Nov 22. Nielsen Jack, the Director of the company, disposed of 31,902 shares for $57.60 on Nov 22. It resulted in a $1,837,555 divestment by the insider. Nielsen Jack sold 24,898 shares at an average price of $57.08 on Nov 21. The insider now owns 2,846,163 shares following the transaction. On Nov 18, Director Nielsen Jack sold 20,800 shares at $57.00 apiece. The transaction was valued at $1,185,600.
Right now, Harmony Biosciences Holdings Inc. (HRMY) has a P/E ratio of about 22.52. Besides these, the trailing price-to-sales (P/S) ratio of 8.37, the price-to-book (PB) ratio of 9.90, and the price-to-cash flow ratio of 21.62 may also be considered.
In the three months ended June 29, Harmony Biosciences Holdings Inc.’s quick ratio stood at 3.50, while its current ratio was 3.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.55, and the total debt-to-equity ratio was 0.56. On the profitability front, the trailing twelve-month gross margin is 81.40% percent. In the year ended June 29, operating margins totaled 25.20%. Based on annual data, HRMY earned $249.92 million in gross profit and brought in $305.44 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 15.50%. Return on equity (ROE) for the past 12 months was 62.80%.
In Harmony Biosciences Holdings Inc.’s quarter-end financial report for June 29, it reported total debt of $189.73 million against cash and short-term investments of $46.42 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HRMY’s revenue rose 31.12% to $107.03 million during the quarter, while net income inched up to $117.21 million. While analysts expected Harmony Biosciences Holdings Inc. to report $0.44 quarterly earnings, the actual figure was $0.39 per share, beating the consensus estimate by -11.40%. During the quarter, the company generated $18.38 million in EBITDA. The liabilities of Harmony Biosciences Holdings Inc. were 299.58 million at the end of its most recent quarter ended June 29, and its total debt was $195.16 million. The value of shareholders’ equity is $59.32 million.
This quick technical analysis looks at Harmony Biosciences Holdings Inc.’s (HRMY) price momentum. With a historical volatility rate of 34.62%, the RSI 9-day stood at 56.31% on 23 November.
With respect to its five-day moving average, the current Harmony Biosciences Holdings Inc. price is up by +3.34% percent or $1.86. At present, HRMY shares trade +11.78% above its 20-day simple moving average and +9.21% percent above its 100-day simple moving average. However, the stock is currently trading approximately +27.02% above its SMA50 and +49.82% above its SMA200.
Stochastic coefficient K was 53.20% and Stochastic coefficient D was 50.81%, while ATR was 2.60. Given the Stochastic reading of 52.30% for the 14-day period, the RSI (14) reading has been calculated as 57.96%. As of today, the MACD Oscillator reading stands at 0.58, while the 14-day reading stands at 0.19.
Jefferies upgraded its rating on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to a Buy in a note to investors on October 14, 2022. The analysts firm previously had a Hold rating on the stock.Harmony Biosciences Holdings Inc. (HRMY) has been rated Buy by analysts. According to 0 brokerage firms, HRMY is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Harmony Biosciences Holdings Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $66.50, the current consensus forecast for the stock is $52.00 – $71.00. Based on these forecasts, analysts predict Harmony Biosciences Holdings Inc. (HRMY) will achieve an average price target of $64.88.